Get started
Author

Marisa Schmitt

Observed institution: Heidelberg Pharma (Germany)
ORCID: 0009-0009-1374-3421
Observed ORCID: 0009-0009-1374-3421
OpenAlex ID: A5089278824
Abstract 1523: Subcutaneous dosing of amatoxin-based ADCs increases the therapeutic index
2023 · Kristin Decker, Marija Vranic, et al. · Cancer Research · 8
Abstract 7183: Liver toxicity of amanitin-based antibody drug conjugates (ATACs) is caused by unspecific uptake of the ATAC into liver cells
2024 · Christian Orlik, Kristin Decker, et al. · Cancer Research · 2
Abstract 1558: HDP-201 - a novel multimeric linker exatecan-based ADC targeting Guanylyl cyclase C (GCC) for treatment of gastrointestinal malignancies
2025 · Sarah Jane Neuberth, Christian Orlik, et al. · Cancer Research · 1
Amanitin-Based Fc-Small Molecule–Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy
2026 · Daniela Carraturo, Francesca Gallo, et al. · Molecular Cancer Therapeutics
PDF
Abstract 1761: Treatment with antibody-targeted amanitin conjugates induces tolerability in preclinical models without triggering tolerance
2022 · Kristin Decker, Marisa Schmitt, et al. · Cancer Research
Works count: 5
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type